Protection Against Insulin Resistance by Apolipoprotein M/Sphingosine-1-Phosphate.


Journal

Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763

Informations de publication

Date de publication:
05 2020
Historique:
received: 14 08 2019
accepted: 02 01 2020
pubmed: 10 1 2020
medline: 28 10 2020
entrez: 10 1 2020
Statut: ppublish

Résumé

Subjects with low serum HDL cholesterol levels are reported to be susceptible to diabetes, with insulin resistance believed to be the underlying pathological mechanism. Apolipoprotein M (apoM) is a carrier of sphingosine-1-phosphate (S1P), a multifunctional lipid mediator, on HDL, and the pleiotropic effects of HDL are believed to be mediated by S1P. In the current study, we attempted to investigate the potential association between apoM/S1P and insulin resistance. We observed that the serum levels of apoM were lower in patients with type 2 diabetes and that they were negatively correlated with BMI and the insulin resistance index. While deletion of apoM in mice was associated with worsening of insulin resistance, overexpression of apoM was associated with improvement of insulin resistance. Presumably, apoM/S1P exerts its protective effect against insulin resistance by activating insulin signaling pathways, such as the AKT and AMPK pathways, and also by improving the mitochondrial functions through upregulation of SIRT1 protein levels. These actions of apoM/S1P appear to be mediated via activation of S1P1 and/or S1P3. These results suggest that apoM/S1P exerts protective roles against the development of insulin resistance.

Identifiants

pubmed: 31915150
pii: db19-0811
doi: 10.2337/db19-0811
doi:

Substances chimiques

APOM protein, human 0
ApoM protein, mouse 0
Apolipoproteins M 0
Blood Glucose 0
Dietary Fats 0
Glycated Hemoglobin A 0
Lipids 0
Lysophospholipids 0
sphingosine 1-phosphate 26993-30-6
Sphingosine NGZ37HRE42

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

867-881

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 by the American Diabetes Association.

Auteurs

Makoto Kurano (M)

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan kurano-tky@umin.ac.jp yatoyuta-tky@umin.ac.jp.

Kazuhisa Tsukamoto (K)

Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
Department of Metabolism, Diabetes and Nephrology, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan.

Tomo Shimizu (T)

Research & Development Division, Tsukuba Research Institute, Sekisui Medical Co., Ltd., Ibaraki, Japan.

Hidetoshi Kassai (H)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kazuki Nakao (K)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Atsu Aiba (A)

Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Masumi Hara (M)

Department of Internal Medicine, Mizonokuchi Hospital, Teikyo University School of Medicine, Kanagawa, Japan.

Yutaka Yatomi (Y)

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan kurano-tky@umin.ac.jp yatoyuta-tky@umin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH